These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22360644)

  • 21. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
    Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
    Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
    Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer.
    Morita R; Sato K; Nakano M; Miura H; Odaka H; Nobori K; Kosaka T; Sano M; Watanabe H; Shioya T; Ito H
    J Cancer Res Clin Oncol; 2011 Dec; 137(12):1849-57. PubMed ID: 21927909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall lung cancer patients in China: A retrospective institution analysis of 132 patients.
    Cheng B; Cai XJ; Chen LY; Wang Z; Weng L; Li QL
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C84-8. PubMed ID: 26323932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer.
    Du L; Morgensztern D
    Cancer J; 2015; 21(5):366-70. PubMed ID: 26389760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
    Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
    Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer.
    Zhang Z; Xiao Y; Zhao J; Chen M; Xu Y; Zhong W; Xing J; Wang M
    Respirology; 2016 Apr; 21(3):519-25. PubMed ID: 26661896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
    Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
    Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
    Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
    Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
    Belani CP; Chakraborty BC; Modi RI; Khamar BM
    Ann Oncol; 2017 Feb; 28(2):298-304. PubMed ID: 27831503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
    Zhang S; He L; Dai N; Guan W; Shan J; Yang X; Zhong Z; Qing Y; Jin F; Chen C; Yang Y; Wang H; Baugh L; Tell G; Wilson DM; Li M; Wang D
    Oncotarget; 2016 Nov; 7(47):77482-77494. PubMed ID: 27813497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution.
    Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Isikdogan A
    Asian Pac J Cancer Prev; 2012; 13(4):1281-4. PubMed ID: 22799319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Milaki G; Messaritakis I; Koinis F; Kotsakis A; Apostolaki S; Dermitzaki EK; Perraki M; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):101-108. PubMed ID: 28523597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.